# ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN

> **NCT04639024** · PHASE2 · TERMINATED · sponsor: **Gwynn Long, M.D.** · enrollment: 3 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- Myeloproliferative Neoplasm (MDS/MPN)

## Interventions

- **DRUG:** ADCT-301

## Key facts

- **NCT ID:** NCT04639024
- **Lead sponsor:** Gwynn Long, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-07
- **Primary completion:** 2022-11-03
- **Final completion:** 2022-11-03
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** ADCT is reallocating all resources to the phase III program.
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04639024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04639024, "ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04639024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*